Robins LN, Reiger D: Psychiatric Disorders of America: the Epidemiologic Catchment Area study. 1991, The Free Press, New York, New York
Google Scholar
Boydell J, van Os J, McKenzie K, Allardyce J, Goel R, McCreadie RG, Murray RM: Incidence of schizophrenia in ethnic minorities in London: ecological study into interactions with the environment. BMJ. 2001, 323: 1336-1338. 10.1136/bmj.323.7325.1336.
Article
CAS
PubMed
PubMed Central
Google Scholar
Brekke , John S, Prindle C, Bae SW, Long JD: Risks for individuals with schizophrenia who are living in the community. Psychiatr Serv. 2001, 52: 1358-1366. 10.1176/appi.ps.52.10.1358.
Article
CAS
PubMed
Google Scholar
Strakowski SM, Flaum M, Amador X, Bracha HS, Pandurangi AK, Robinson D, Tohen M: Racial differences in the diagnosis of psychosis. Schizophr Res. 1996, 21: 117-124. 10.1016/0920-9964(96)00041-2.
Article
CAS
PubMed
Google Scholar
Adebimpe VR: Overview: American blacks and psychiatry. Transcultural Psychiatry Research Review. 1984, 21: 83-111. 10.1177/136346158402100201.
Article
Google Scholar
Herbeck DM, West JC, Ruditis I, Duffy FF, Fitek DJ, Bell CC, Snowden LR: Variations in the use of second-generation antipsychotics mediation by race among adult psychiatric patients. Psychiatr Serv. 2004, 55: 677-684. 10.1176/appi.ps.55.6.677.
Article
PubMed
Google Scholar
Mallinger JB, Fisher SG, Brown T, Lamberti JS: Racial disparities in the use of second-generation antipsychotics for the treatment of schizophrenia. Psychiatr Serv. 2006, 57: 133-136. 10.1176/appi.ps.57.1.133.
Article
PubMed
Google Scholar
Arnold LM, Strakowski SM, Schwiers ML, Amicone J, Fleck DE, Corey KB, Farrow JE: Sex, ethnicity, and antipsychotic medication use in patients with psychosis. Schizophr Res. 2004, 66: 169-175. 10.1016/S0920-9964(03)00102-6.
Article
PubMed
Google Scholar
Mark TL, Palmer LA, Russo PA, Vasey J: Examination of treatment patterns by race. Ment Health Serv Res. 2003, 5: 241-250. 10.1023/A:1026281118990.
Article
PubMed
Google Scholar
Kuno E, Rothbard AB: Racial disparities in antipsychotic prescription patterns for patients with schizophrenia. Amer J Psychiatry. 2002, 159: 567-572. 10.1176/appi.ajp.159.4.567.
Article
Google Scholar
Van Dorn RA, Swanson JW, Swartz MS, Elbogen EB: The effects of race and criminal justice involvement on access to atypical antipsychotic medications among persons with schizophrenia. Ment Health Serv Res. 2005, 7: 123-134. 10.1007/s11020-005-3783-z.
Article
PubMed
Google Scholar
Opolka JL, Rascati KL, Brown CM, Gibson PJ: Ethnicity and prescription patterns for haloperidol, risperidone, and olanzapine. Psychiatr Serv. 2004, 55: 151-156. 10.1176/appi.ps.55.2.151.
Article
PubMed
Google Scholar
Copeland LA, Zeber JE, Valenstein M, Blow FC: Racial disparity in the use of atypical antipsychotic medications among veterans. Am J Psychiatry. 2003, 160: 1817-1822. 10.1176/appi.ajp.160.10.1817.
Article
PubMed
Google Scholar
Opolka JL, Rascati KL, Brown CM, Barner JC, Johnsrud MT, Gibson PJ: Ethnic differences in use of antipsychotic medication among Texas Medicaid clients with schizophrenia. J Clin Psychiatry. 2003, 64: 635-639. 10.4088/JCP.v64n0603.
Article
PubMed
Google Scholar
Opolka JL, Rascati KL, Brown CM, Gibson PJ: Role of ethnicity in predicting antipsychotic medication adherence. Ann Pharmacother. 2003, 37: 625-30. 10.1345/aph.1C321.
Article
PubMed
Google Scholar
Aliyu M, Calkins ME, Swanson CL, Lyons PD, Savage RM, May R, Wiener H, McLeod-Bryant S, Nimgaonkar VL, Ragland JD, Gur RE, Gur RC, Bradford LD, Edwards N, Kwentus J, McEvoy JP, Santos AB, McCleod-Bryant S, Tennison C, Go RC, Allen TB, PAARTNERS Study Group: Project among African Americans to explore risks for schizophrenia (PAARTNERS): recruitment and assessment methods. Schizophr Res. 2006, 87: 32-44. 10.1016/j.schres.2006.06.027.
Article
PubMed
Google Scholar
Kane JM, Osuntokun O, Kryzhanovskaya LA, Xu W, Stauffer VL, Watson SB, Breier A: A 28-week randomized, double-blind study of olanzapine versus aripiprazole in the treatment of schizophrenia. J Clin Psychiatry. 2009, 70: 572-581. 10.4088/JCP.08m04421.
Article
CAS
PubMed
Google Scholar
Kinon BJ, Lipkovich I, Edwards SE, Adams DH, Ascher-Svanum H, Siris SG: A 24- week randomized study of olanzapine versus ziprasidone in the treatment of schizophrenia and schizoaffective disorder with prominent depressive symptoms. J Clin Psychopharmacol. 2006, 26: 157-162. 10.1097/01.jcp.0000204137.82298.06.
Article
CAS
PubMed
Google Scholar
Kinon BJ, Noordsoy DL, Lu-Siefert H, Gulliver AH, Ascher-Svanum H, Kollack-Walker S: Randomized, double-blind 6 month comparison of olanzapine and quetiapine in patients with schizophrenia and schizoaffective disorder with prominent negative symptoms and poor functioning. J Clin Psychopharmacol. 2006, 26: 453-461. 10.1097/01.jcp.0000236658.16286.25.
Article
CAS
PubMed
Google Scholar
Breier A, Berg PH, Thakore JH, Naber D, Gattaz WF, Cavazzoni P, Walker DJ, Roychowdhury SM, Kane JM: Olanzapine versus ziprasidone: results of the 28-week, double-blind study in patients with schizophrenia. Am J Psychiatry. 2005, 162: 1879-1887. 10.1176/appi.ajp.162.10.1879.
Article
PubMed
Google Scholar
Tran PV, Hamilton SH, Kuntz AJ, Potvin JH, Andersen SW, Beasley C, Tollefson GD: Double-blind comparison of olanzapine versus risperidone in the treatment of schizophrenia and other psychotic disorders. J Clin Psychopharmacol. 1997, 17: 407-418. 10.1097/00004714-199710000-00010.
Article
CAS
PubMed
Google Scholar
Keefe RS, Young CA, Rock SL, Purdon SE, Gold JM, Breier A, HGGN Study Group: One-year double-blind study of the neurocognitive efficacy of olanzapine, risperidone, and haloperidol in schizophrenia. Schizophr Res. 2006, 81: 1-15. 10.1016/j.schres.2005.07.038.
Article
PubMed
Google Scholar
Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA. 2001, 285: 2486-2497. 10.1001/jama.285.19.2486.
American Diabetes Association: Diagnosis and classification of diabetes mellitus. Diabetes Care. 2005, 28 (Suppl 1): S37-42.
Article
Google Scholar
Canive JM: CATIE Study: Effectiveness among Ethnic/Racial Minorities. 2009, Presentation: Latin Behavioral Health Institute
Google Scholar
Ciliberto N, Bossie CA, Urioste R, Lasser RA: Lack of impact of race on the efficacy and safety of long-acting risperidone versus placebo in patients with schizophrenia or schizoaffective disorder. Int Clin Psychopharmacol. 2005, 20: 207-212. 10.1097/00004850-200507000-00003.
Article
PubMed
Google Scholar
Lieberman JL, Stroup TS, McEvoy JP, Swartz MS, Rosenheck RA, Perkins DO, Keefe RS, Davis SM, Davis CE, Lebowitz BD, Severe J, Hsiao JK, Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Investigators: Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med. 2005, 353: 1209-1223. 10.1056/NEJMoa051688.
Article
CAS
PubMed
Google Scholar
Emsley RA, Roberts MC, Rataemane S, Pretorius J, Oosthuizen PP, Turner J, Niehaus DJ, Keyter N, Stein DJ: Ethnicity and treatment response in schizophrenia: comparisons of 3 ethnic groups. J Clin Psychiatry. 2002, 63: 9-14.
Article
PubMed
Google Scholar
de Leon J, Diaz FJ, Josiassen RC, Cooper TB, Simpson GM: Weight gain during a double-blind multidosage clozapine study. J Clin Psychopharmacol. 2007, 27: 22-27. 10.1097/JCP.0b013e31802e513a.
Article
CAS
PubMed
Google Scholar
Mackin P, Bishop D, Watkinson H, Gallagher P, Ferrier IN: Metabolic disease and cardiovascular risk in people treated with antipsychotics in the community. Br J Psychiatry. 2007, 191: 23-29. 10.1192/bjp.bp.106.031716.
Article
PubMed
Google Scholar
Newcomer JW: Second-generation (atypicals) antipsychotics and metabolic effects: a comprehensive literature review. CNS Drugs. 2005, 19 (Suppl 1): 1-93.
CAS
PubMed
Google Scholar
Lamberti JS, Olson D, Crilly JF, Olivares T, Williams GC, Tu X, Tang W, Wiener K, Dvorin S, Dietz MB: Prevalence of the metabolic syndrome among patients receiving clozapine. Am J Psychiatry. 2006, 163: 1273-1276. 10.1176/appi.ajp.163.7.1273.
Article
PubMed
Google Scholar
Ananth J, Gunatilake S, Aquino S, Bach V, Costa J: Are African American patients at a higher risk for olanzapine-induced glucose intolerance?. Psychopharmacology (Berl). 2001, 157: 324-325. 10.1007/s002130100862.
Article
CAS
Google Scholar
Ader M, Garvey WT, Phillips LS, Nemeroff CB, Gharabawi G, Mahmoud R, Greenspan A, Berry SA, Musselman DL, Morein J, Zhu Y, Mao L, Bergman RN: Ethnic heterogeneity in glucoregulatory function during treatment with atypical antipsychotics in patients with schizophrenia. J Psychiatr Res. 2008, 48: 1076-1085. 10.1016/j.jpsychires.2008.01.004.
Article
Google Scholar
Meyer JM, Rosenblatt LC, Kim E, Baker RA, Whitehead R: The moderating impact of ethnicity on metabolic outcomes during treatment with olanzapine and aripiprazole in patients with schizophrenia. J Clin Psychiatry. 2009, 70: 318-325. 10.4088/JCP.08m04267.
Article
CAS
PubMed
Google Scholar
Krakowski M, Czobor P, Citrome L: Weight gain, metabolic parameters, and the impact of race in aggressive inpatients randomized to double-blind clozapine, olanzapine or haloperidol. Schizophr Res. 2009, 110: 95-102. 10.1016/j.schres.2009.02.006.
Article
PubMed
Google Scholar
Ormerod S, McDowell SE, Coleman JJ, Ferner RE: Ethnic differences in the risks of adverse reactions to drugs used in the treatment of psychoses and depression: a systematic review and meta-analysis. Drug Saf. 2008, 31: 597-607. 10.2165/00002018-200831070-00005.
Article
CAS
PubMed
Google Scholar
Hodgkinson CA, Goldman D, Ducci F, DeRosse P, Caycedo DA, Newman ER, Kane JM, Roy A, Malhotra AK: The FEZ1 gene shows no association to schizophrenia in Caucasian or African American populations. Neuropsychopharmacology. 2007, 32: 190-196. 10.1038/sj.npp.1301177.
Article
CAS
PubMed
Google Scholar
Grossman I, Sullivan PF, Walley N, Liu Y, Dawson JR, Gumbs C, Gaedigk A, Leeder JS, McEvoy JP, Weale ME, Goldstein DB: Genetic determinants of variable metabolism have little impact on the clinical use of leading antipsychotics in the CATIE study. Genet Med. 2008, 10: 720-729. 10.1097/GIM.0b013e3181863239.
Article
CAS
PubMed
PubMed Central
Google Scholar
Campbell DB, Lange LA, Skelly T, Lieberman J, Levitt P, Sullivan PF: Association of RGS2 and RGS5 variants with schizophrenia symptom severity. Schizophr Res. 2008, 101: 67-75. 10.1016/j.schres.2008.01.006.
Article
PubMed
PubMed Central
Google Scholar
Weickert CS, Miranda-Angulo AL, Wong J, Perlman WR, Ward SE, Radhakrishna V, Straub RE, Weinberger DR, Kleinman JE: Variants in the estrogen receptor alpha gene and its mRNA contribute to risk for schizophrenia. Hum Mol Genet. 2008, 17: 2293-2309. 10.1093/hmg/ddn130.
Article
CAS
PubMed
PubMed Central
Google Scholar
Fijal BA, Kinon BJ, Kapur S, Stauffer VL, Conley RR, Jamal HH, Kane JM, Witte MM, Houston JP: Candidate-gene association analysis of response to risperidone in African-American and white patients with schizophrenia. Pharmacogenomics J. 2009, 9: 311-318. 10.1038/tpj.2009.24.
Article
CAS
PubMed
Google Scholar